Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions
John R. Zibert, … , Lone Skov, Michael P. Schön
John R. Zibert, … , Lone Skov, Michael P. Schön
Published December 6, 2010
Citation Information: J Clin Invest. 2011;121(1):410-421. https://doi.org/10.1172/JCI41295.
View: Text | PDF
Research Article Dermatology

Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions

Abstract

Dysregulated angiogenesis is a hallmark of chronic inflammatory diseases, including psoriasis, a common skin disorder that affects approximately 2% of the population. Studying both human psoriasis in 2 complementary xenotransplantation models and psoriasis-like skin lesions in transgenic mice with epidermal expression of human TGF-β1, we have demonstrated that antiangiogenic non-viral somatic gene therapy reduces the cutaneous microvasculature and alleviates chronic inflammatory skin disorders. Transient muscular expression of the recombinant disintegrin domain (RDD) of metargidin (also known as ADAM-15) by in vivo electroporation reduced cutaneous angiogenesis and vascularization in all 3 models. As demonstrated using red fluorescent protein–coupled RDD, the treatment resulted in muscular expression of the gene product and its deposition within the cutaneous hyperangiogenic connective tissue. High-resolution ultrasound revealed reduced cutaneous blood flow in vivo after electroporation with RDD but not with control plasmids. In addition, angiogenesis- and inflammation-related molecular markers, keratinocyte proliferation, epidermal thickness, and clinical disease scores were downregulated in all models. Thus, non-viral antiangiogenic gene therapy can alleviate psoriasis and may do so in other angiogenesis-related inflammatory skin disorders.

Authors

John R. Zibert, Katrin Wallbrecht, Margarete Schön, Lluis M. Mir, Grete K. Jacobsen, Veronique Trochon-Joseph, Céline Bouquet, Louise S. Villadsen, Ruggero Cadossi, Lone Skov, Michael P. Schön

×

Figure 5

RDD gene therapy reduces cutaneous vascularization and alleviates psoriasis in human skin transplanted onto immunodeficient mice.

Options: View larger image (or click on image) Download as PowerPoint
RDD gene therapy reduces cutaneous vascularization and alleviates psoria...
(A) Psoriatic skin with a full-fledged phenotype was transplanted onto Prkdcscid mice, and recipient mice were either left untreated (representative of n = 12 mice) or subjected to gene therapy with pVAX-RFP (representative of n = 14 mice) or pVAX-RDD (representative of n = 13 mice). The macroscopic aspect of the blood vessels on the underside of the skin transplants demonstrates that gene therapy with RDD reduces cutaneous vascularization. Original magnification, ~×3. (B) Transplanted psoriatic skin was analyzed by immunohistochemistry using the indicated reagents detecting blood vessels. Somatic gene therapy with pVAX-RDD results in reduction of both number and size of cutaneous blood vessels as compared with that of the controls. Blood vessels of human (CD31 and SMA) as well as murine (BS-1) origin are affected. Scale bar: 50 μm. (C) Transplants of fully developed psoriasis transplanted onto Prkdcscid mice were further analyzed by staining with H&E (left panels) or by immunohistochemistry using the indicated antibodies detecting proliferating cells (Ki67) or T cells (CD3). Both the epidermal thickness and the number of proliferating epidermal keratinocytes are reduced in transplants from mice treated by RDD gene therapy. Scale bar: 50 μm. (D) Quantitative morphometric analysis of transplants from Prkdcscid mice. The top graph depicts the epidermal thickness as determined by blinded measurements. The bottom graph shows the number of proliferating epidermal cells in mice subjected to RDD gene therapy compared with that of the controls. Values represent mean ± SD. ***P< 0.001.